Market Access News | pharmaphorum

News

Australia joins EU in turning down Alzheimer's drug Leqembi

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

News

FDA set to decide on GSK's gepotidacin antibiotic in March

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 yea

News

US digital health spending set to increase, survey finds

Health plans, employers, and healthcare providers remain committed to adopting digital solutions and expect to increase their spending on the category, according to a recent poll.<

News

LEO launches chronic hand eczema drug in its first market

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE).

News

Lilly pledges £279m to UK for biotech hub and obesity plan

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.

News

Baxter medicines in short supply after hurricane hits plant

Damage to a Baxter manufacturing facility caused by Hurricane Helene, which rolled across the east US a couple of weeks ago, has led to shortages in some critical medicines.

Australia joins EU in turning down Alzheimer's drug Leqembi

FDA set to decide on GSK's gepotidacin antibiotic in March

US digital health spending set to increase, survey finds

LEO launches chronic hand eczema drug in its first market

Lilly pledges £279m to UK for biotech hub and obesity plan

Baxter medicines in short supply after hurricane hits plant

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks